Located in Glasgow and Edinburgh (Scotland), TC BioPharm is developing a cutting-edge and innovative autologous anti-cancer immunotherapy - formulating a treatment for a wide-variety of different tumour types. Founded late 2013, the Company is planning to commence UK clinical studies Q1, 2015.
TC BioPharm's proprietary cell therapy manufacturing process comprises several steps. The first involves isolation of peripheral blood mononuclear cells; the second involves selection/activation of γδ T lymphocytes; the final stage requires culture expansion in a GMP (Good Manufacturing Practice) environment, providing therapeutically relevant cell numbers prior to administration. Although there are many different approaches to T cell immunotherapy, the process used by TC BioPharm has a compelling clinical safety (and efficacy) record, demonstrated by an extensive cohort of published case histories.
The therapeutic approach has also been implemented to successfully treat various tumour types including gastric cancer, renal cell carcinoma, hepatocellular carcinoma, pancreatic cancer, acute myeloid leukaemia, multiple myeloma and acute lymphoblastic leukaemia. Evidence from previous clinical studies indicated, that - when combination treatments are performed, γδ T-cell therapy does not have a negative impact on adjunctive regimes.
TC BioPharm is building a team of dedicated, entrepreneurial individuals driven by desire to develop treatments which significantly improve patient’s Quality of Life. If you are interested in working in an innovative, dynamic environment, and share our passion for ‘making a difference’ – we would be delighted to meet with you.